Cautionary Statement 2 This presentation contains "forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” "potential" and other words of similar meaning, including statements regarding our estimated revenues and financial projections, our ability to achieve high levels of growth, the potential for our products under development to be game-changing, the potential of our next generation prostate markers to reduce biopsies and increase detection of cancer, our ability to develop a lead Alzheimer’s test and additional diagnostic products, the ability of our Alzheimer’s diagnostic test to distinguish Alzheimer’s disease from other dementias, our ability to develop certain therapeutics, new drugs and vaccines, including for the treatment of genetic diseases, cancers, neurological and metabolic disorders, our ability to develop and commercialize compounds that prevent the progression of neurodegenerative diseases, our ability to develop, test and launch new products, the expected timing of the studies and trials relating to our products under development, the outcome of our clinical trials and validation studies and that such outcomes will support commercialization, the expected size of the market for certain of our products under development, the potential benefits of our products under development, our ability to successfully develop and commercialize our product candidates such as simple blood tests for Alzheimer’s, Neuromylelitis Optica, Multiple Sclerosis and other neurological disorders, lung, pancreatic, and other cancers and autoimmune diseases, as well as products for other markets such as urology, women’s health, cardiology and infectious disease, our ability to develop and commercialize next generation prostate markers, and the timing of clinical trials and expected U.S. and European regulatory approvals for our product candidates and the commercial launch of our product candidates, as well as other non-historical statements. These forward-looking statements are only predictions and reflect our views as of the date they were made, and we undertake no obligation to update such statements. Such statements are subject to many risks and uncertainties that could cause our activities or actual results to differ materially from the activities and results anticipated in forward-looking statements, including risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, general market factors, competitive product development, product availability, federal and state regulations and legislation, delays associated with development of novel technologies, unexpected difficulties and delays in validating and testing product candidates, the regulatory process for new products and indications, manufacturing issues that may arise, the cost of funding lengthy research programs, the need for and availability of additional capital, the possibility of infringing a third party’s patents or other intellectual property rights, the uncertainty of obtaining patents covering our products and processes and in successfully enforcing them against third parties, and the possibility of litigation, among other factors, including all of the risks identified under the heading Risk Factors in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. |
